Haemonetics (NYSE:HAE – Get Free Report)‘s stock had its “strong-buy” rating restated by Raymond James in a research report issued on Friday,Benzinga reports. They currently have a $115.00 price objective on the medical instruments supplier’s stock, down from their prior price objective of $120.00. Raymond James’ target price would indicate a potential upside of 89.04% from the company’s previous close.
HAE has been the topic of a number of other research reports. JMP Securities cut their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research note on Friday. Bank of America lowered Haemonetics from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $95.00 to $68.00 in a report on Friday. JPMorgan Chase & Co. initiated coverage on Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Barrington Research lowered their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday. Finally, Needham & Company LLC lowered their target price on Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a report on Friday. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $101.67.
Read Our Latest Research Report on HAE
Haemonetics Price Performance
Haemonetics (NYSE:HAE – Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. Analysts expect that Haemonetics will post 4.59 earnings per share for the current fiscal year.
Institutional Trading of Haemonetics
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Global Alpha Capital Management Ltd. acquired a new position in shares of Haemonetics in the 3rd quarter valued at $806,000. Loomis Sayles & Co. L P increased its position in shares of Haemonetics by 8.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier’s stock valued at $13,171,000 after acquiring an additional 12,310 shares during the period. BNP Paribas Financial Markets increased its position in shares of Haemonetics by 174.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock valued at $1,362,000 after acquiring an additional 10,774 shares during the period. Westfield Capital Management Co. LP increased its position in shares of Haemonetics by 10.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock valued at $66,206,000 after acquiring an additional 80,783 shares during the period. Finally, Boston Trust Walden Corp increased its position in shares of Haemonetics by 13.1% in the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock valued at $71,500,000 after acquiring an additional 106,114 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.
About Haemonetics
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
See Also
- Five stocks we like better than Haemonetics
- What is the S&P/TSX Index?
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- Stock Market Sectors: What Are They and How Many Are There?
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
- Are Penny Stocks a Good Fit for Your Portfolio?
- High-Momentum ETFs Leading the Market This Year
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.